Compare Moody's Corporation (MCO) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Tango Therapeutics Inc. — how do they compare? Moody's Corporation trades at $463.02 (market cap $80.14B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Moody's Corporation is far larger — about 21.4× Tango Therapeutics Inc.'s market cap, and Moody's Corporation pays a 0.89% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moody's Corporation for 133 Days and Tango Therapeutics Inc. for 0 Days on average.
| MCO | TNGX | |
|---|---|---|
Market Cap | $80.14B | $3.74B |
Volume | 829,155 | 3,438,781 |
Sector | Financials | Health |
52-Week High | $539.61 | $32.90 |
52-Week Low | $412.23 | $7.50 |
Typical Hold Time | 133 Days | 0 Days |
Enterprise Value | $86.17B | $2.76B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCO trades at $464.13, down 1.35% today, but maintains a bullish technical outlook with strong support at $464. Revenue grew to $7.72B in 2025 with a net income margin of 34.25%, and the company has beaten earnings estimates for three consecutive quarters. Recent news highlights strategic moves like a minority stake in PhilRatings to bolster Asia-Pacific presence and a top RiskTech100 ranking for the fifth year.
The outlook remains positive with a consensus price target of $536.40, implying 15.6% upside, supported by robust profitability and growth initiatives. Key risks include high valuation multiples and exposure to economic cycles affecting credit demand. Analyst sentiment is predominantly bullish with 18 buy ratings.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
